1,644 Shares in Axon Enterprise, Inc $AXON Acquired by United Services Automobile Association

Key Points

• United Services Automobile Association acquired 1,644 shares of Axon Enterprise, Inc, valued at approximately $879,000, marking a significant investment in the biotechnology sector.
• Analysts have boosted their price targets for Axon Enterprise, with Goldman Sachs raising theirs from $730.00 to $830.00 and Bank of America increasing theirs to $1,000.00, reflecting strong market sentiments towards the company.
• In recent insider activity, President Joshua Isner sold over 15,900 shares of Axon stock for nearly $11.88 million, while other executives also made smaller transactions, indicating potential shifts in insider confidence.

United Services Automobile Association acquired a new position in shares of Axon Enterprise, Inc (NASDAQ:AXON - Free Report) in the first quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 1,644 shares of the biotechnology company's stock, valued at approximately $879,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Vanguard Group Inc. increased its position in shares of Axon Enterprise by 2.2% during the 1st quarter. Vanguard Group Inc. now owns 8,632,008 shares of the biotechnology company's stock worth $4,540,005,000 after purchasing an additional 185,571 shares during the last quarter. Alliancebernstein L.P. increased its position in shares of Axon Enterprise by 15.9% during the 1st quarter. Alliancebernstein L.P. now owns 1,284,935 shares of the biotechnology company's stock worth $675,812,000 after purchasing an additional 175,890 shares during the last quarter. Westfield Capital Management Co. LP increased its position in shares of Axon Enterprise by 29.8% during the 1st quarter. Westfield Capital Management Co. LP now owns 927,801 shares of the biotechnology company's stock worth $487,977,000 after purchasing an additional 212,931 shares during the last quarter. GAMMA Investing LLC increased its position in shares of Axon Enterprise by 58,725.5% during the 1st quarter. GAMMA Investing LLC now owns 764,731 shares of the biotechnology company's stock worth $402,210,000 after purchasing an additional 763,431 shares during the last quarter. Finally, Northern Trust Corp increased its position in shares of Axon Enterprise by 1.2% during the 1st quarter. Northern Trust Corp now owns 725,720 shares of the biotechnology company's stock worth $381,692,000 after purchasing an additional 8,794 shares during the last quarter. 79.08% of the stock is owned by institutional investors and hedge funds.

Axon Enterprise Stock Up 0.7%

Shares of AXON traded up $5.02 during midday trading on Friday, hitting $756.13. The company had a trading volume of 303,694 shares, compared to its average volume of 447,052. The company's 50-day simple moving average is $761.10 and its 200-day simple moving average is $688.38. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.71 and a current ratio of 2.95. The firm has a market capitalization of $59.36 billion, a P/E ratio of 186.70, a P/E/G ratio of 27.75 and a beta of 1.40. Axon Enterprise, Inc has a 1 year low of $375.71 and a 1 year high of $885.91.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last announced its quarterly earnings data on Monday, August 4th. The biotechnology company reported $2.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.54 by $0.58. The business had revenue of $668.54 million during the quarter, compared to analysts' expectations of $641.77 million. Axon Enterprise had a return on equity of 6.80% and a net margin of 13.64%.The business's quarterly revenue was up 32.6% compared to the same quarter last year. During the same quarter last year, the business posted $1.20 EPS. Axon Enterprise has set its FY 2025 guidance at EPS. As a group, sell-side analysts expect that Axon Enterprise, Inc will post 5.8 EPS for the current year.

Analysts Set New Price Targets

AXON has been the subject of a number of recent analyst reports. Morgan Stanley set a $885.00 price objective on Axon Enterprise and gave the stock an "overweight" rating in a research report on Friday, July 11th. Zacks Research cut Axon Enterprise from a "strong-buy" rating to a "hold" rating in a report on Tuesday, September 2nd. Craig Hallum upgraded Axon Enterprise from a "hold" rating to a "buy" rating and set a $900.00 target price for the company in a report on Tuesday, August 5th. Wolfe Research initiated coverage on Axon Enterprise in a report on Monday, July 7th. They set an "outperform" rating for the company. Finally, UBS Group restated a "neutral" rating and set a $840.00 target price (up from $820.00) on shares of Axon Enterprise in a report on Tuesday, August 5th. Thirteen analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $837.69.

Insiders Place Their Bets

In related news, Director Hadi Partovi acquired 1,358 shares of the firm's stock in a transaction dated Wednesday, August 13th. The stock was acquired at an average price of $740.00 per share, for a total transaction of $1,004,920.00. Following the purchase, the director owned 237,938 shares of the company's stock, valued at $176,074,120. This represents a 0.57% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CAO Jennifer H. Mak sold 75 shares of Axon Enterprise stock in a transaction dated Wednesday, September 3rd. The shares were sold at an average price of $723.50, for a total value of $54,262.50. Following the completion of the transaction, the chief accounting officer owned 15,080 shares of the company's stock, valued at $10,910,380. The trade was a 0.49% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 44,790 shares of company stock worth $34,304,947. Corporate insiders own 5.70% of the company's stock.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.